Jansen 2017 MiP2017
Calanus oil (a novel marine oil), as well as exenatide (GLP-1 agonist), reduces the deposition of intra-abdominal fat in adipose tissue during high-fat feeding. To test the hypothesis that targeted reduction of intra-abdominal fat can recover metabolic flexibility of the heart, which is otherwise lost in obesity.
Female C57bl/6J mice received high-fat diet (HFD) or normal chow for 12 wks in order to induce obesity. Thereafter, the HFD mice were treated for 8 wks with Calanus oil (2%), exenatide (10 µg/kg/day), or the two treatments combined. Non-treated chow- and HFD-fed mice served as lean and obese controls, respectively. At the end of the treatment period, substrate oxidation (radioisotope technique) and tolerance to ischemia-reperfusion were examined, using Langendorff-perfused hearts.
Both Calanus oil and exenatide had a clear anti-obesogenic effect, as demonstrated by significantly reduced intra-abdominal fat stores at the end of the treatment period. This was associated with improved myocardial glucose oxidation, relative to non-treated obese controls. Pre-ischemic left ventricular (LV) function was not different between the groups, but hearts from Calanus oil-treated obese mice showed increased post-ischemic functional recovery relative to hearts from non-treated obese mice. No synergism between Calanus oil and exenatide treatment was observed.
In conclusion, obesity-related loss of myocardial metabolic flexibility was counteracted both by Calanus oil and exenatide treatment. In Calanus oil-treated mice, this was associated with increased post-ischemic recovery of LV function.
• Bioblast editor: Beno M, Kandolf G • O2k-Network Lab: NO Tromsoe Larsen TS
Labels: MiParea: Exercise physiology;nutrition;life style Pathology: Obesity
- Dept Medical Biol, Fac Health Sc, UiT The Arctic Univ Norway, Norway. - [email protected]